How Our Laser Drilling System Supports FDA 21 CFR Part 11 Compliance

Introduction: As osmotic controlled-release tablets (such as Metformin and Nifedipine) become widely adopted, laser drilling systems play a critical role in ensuring consistent release performance. However, for global pharmaceutical markets, hardware precision alone is no longer enough—compliance with FDA 21 CFR Part 11 has become a decisive purchasing factor.

---

Compliance Challenges in Laser Drilling Systems

• Lack of data recording: Conventional precision laser systems often fail to capture process data, making traceability impossible.
• No user access control: Without permission management or operation logs, audits cannot identify responsibility.
• Untracked parameter changes: Adjustments not linked to user IDs raise concerns about data integrity.
• Missing e-signature functions: The inability to provide secure digital signatures limits acceptance in regulated markets.

---

Key Functions of a Compliant Laser Drilling System

• Multi-user login with role-based access control
• Parameter adjustment only after authenticated login, with automatic operation logs
• Comprehensive audit trail for every run and modification

---

HUANGHAI’s Solution — The Olando K3-2 System

The Olando K3-2 Pharmaceutical Laser Drilling System integrates functionality designed to support 21 CFR Part 11 from design to software:

• Industrial control system with touch-screen interface, access hierarchy, and audit trail module
• Real-time monitoring with per-tablet records
• Dual-station vision inspection with tablet defect detection.
• Siemens PLC and imported electrical components as standard
• Validation documentation templates available; on-site validation is carried out by the end user.

---

Key Takeaway

Precision drilling defines product quality; compliance defines market access. The Olando K3-2 is designed to support 21 CFR Part 11 compliance.

Learn more about the Olando K3-2 Pharmaceutical Laser Drilling System.

---

Frequently Asked Questions

Q: How does laser drilling create controlled-release tablets?

A: Laser drilling creates a precise aperture in the tablet coating, forming the drug delivery orifice for osmotic pump tablet systems (OROS technology). The osmotic pressure differential between the tablet core and gastrointestinal fluids drives API release through this aperture at a controlled rate. Hole diameter, depth (blind vs. through-hole), and position are critical parameters. The Olando K3-2 offers ±0.1 mm accuracy and up to 120,000 tablets/hour (based on a 15 mm tablet), with closed-loop vision inspection.

Q: Can the Olando K3-2 drill blind holes and through-holes?

A: Yes — the Olando K3-2 offers 0.9 mm blind/through-hole precision with ±0.05 mm hole depth consistency.

Q: What tablet shapes and sizes can the Olando K3-2 process?

A: The Olando K3-2 handles bilayer round tablets. Supported tablet diameters range from 6 mm to 20 mm. The system processes up to 120,000 tablets/hour (based on a 15 mm tablet).

Q: Is the laser drilling system designed to support FDA 21 CFR Part 11 requirements?

A: The Olando K3-2 Laser Drilling System is designed for cGMP environments, uses a Siemens PLC, and is designed to support 21 CFR Part 11 compliance (audit trail, electronic records, access control). For a full Part 11 workflow (final compliance is established by the end user's own validation), integrate the system's data outputs into a validated manufacturing execution system (MES). Reference customers include Shanghai Modern Pharmaceutical (12 installed units for Nifedipine CR) and Shanghai Xinyi Pharmaceutical (3 units for Doxazosin Mesylate).

Q: What are the ongoing maintenance requirements for laser drilling equipment?

Preventive maintenance should be incorporated into your equipment qualification protocol (IQ/OQ/PQ). Request our service agreement terms.